NHS Fast-Tracks IV Safety Tech, Targeting Patient Harm and Hidden Costs

LONDON, UK – July 22, 2026 – The UK’s National Health Service (NHS) is accelerating the adoption of a disruptive technology designed to prevent one of the most common and costly sources of patient harm in hospitals. Virginia-based ivWatch, LLC announced its continuous IV site monitoring system has been selected for the NHS Supply Chain’s Innovation Products pathway, a move that slashes years from the typical procurement timeline and provides a direct route for NHS Trusts to acquire the technology.

The decision marks a significant strategic shift, signalling the NHS’s commitment to rapidly integrating clinically-proven solutions that address systemic safety issues. The technology targets IV infiltration and extravasation—dangerous complications where intravenous fluids leak into surrounding tissue—by providing a crucial early warning system that human observation alone often misses.

The Hidden Cost of a Common Procedure

Peripheral intravenous (IV) therapy is ubiquitous in modern medicine, ranking among the most frequent procedures performed in NHS hospitals. Yet, its failure rate is alarmingly high, with some reports indicating that up to 50% of IVs fail. A primary cause of this failure is infiltration or extravasation, which occurs when a catheter dislodges from a vein, leaking fluids and medications directly into a patient's tissue.

While often under-recognised, the consequences range from painful swelling and bruising to severe tissue necrosis, nerve damage, and even limb amputation. Between 2011 and 2021, NHS Resolution, the body handling claims against the health service, paid out over £15.6 million for 444 claims related to these preventable injuries. This figure only captures the most severe cases that result in legal action, hinting at a much larger, unquantified cost in terms of patient suffering, extended hospital stays, and additional treatments.

The current standard of care relies on intermittent visual and manual checks by busy nursing staff. This method is inherently flawed, especially when IV sites are obscured by dressings, or when patients—such as infants or the critically ill—cannot communicate pain. By the time swelling or discoloration becomes visible, significant damage may have already occurred.

A Technological Sentinel Against Avoidable Harm

ivWatch's system acts as a technological sentinel, offering a non-invasive, continuous second set of eyes on the IV site. Using a patented optical sensor and a predictive algorithm, the device monitors changes in the tissue's optical properties. It is designed to detect the earliest signs of fluid leakage, often hours before physical symptoms become apparent, and alerts clinicians to a potential problem.

This early detection is the critical difference. Clinical trials and real-world deployment within the NHS have yielded dramatic results. A pilot program championed by Andrew Barton, Nurse Consultant in IV Therapy at Frimley Health NHS Foundation Trust, has been a resounding success. His work, which earned the HSJ Patient Safety Pilot Program of the Year award, demonstrated the system's power.

"Spearheading the ivWatch initiative has been a game-changer for our IV therapy practice," said Barton, who is also Chairman of the National Infusion and Vascular Access Society (NIVAS). "We have witnessed a remarkable reduction in extravasation incidents, improving patient safety and staff confidence. The expeditious process of the NHS Supply Chain Innovation Products pathway underscores the urgency and tangible impact of ivWatch."

In a study overseen by Barton, the ivWatch system detected 100% of infiltration events before a clinician could visually identify them. Over a two-year deployment in NHS units under his leadership, there have been no reported IV extravasation injuries, a testament to the technology's preventative power.

This impact is echoed by NHS leaders focused on systemic improvements. "In my ongoing efforts to elevate patient safety standards across the NHS, I've seen firsthand how early detection technologies like ivWatch can transform IV care," stated Maya Aquino-Guerrero, a Patient Safety Champion at NHS Supply Chain. "This technology embodies the kind of innovation we need to protect patients and ensure the best use of NHS resources."

A New Blueprint for MedTech Adoption

The most significant business implication of this announcement is not just the technology itself, but the speed of its approval. Navigating NHS procurement can be a years-long marathon for MedTech companies. By fast-tracking ivWatch onto the Innovation Products pathway, the NHS is creating a new blueprint for how it evaluates and adopts high-impact solutions.

This expedited route signals to the global medical technology market that the NHS is serious about removing bureaucratic barriers when a clear, evidence-backed solution to a major patient safety and cost issue is presented. For a healthcare system often perceived as slow to innovate, this move represents a pragmatic and agile approach to problem-solving. It provides a ready-to-implement solution for NHS Trusts, eliminating the need for them to conduct their own lengthy and costly procurement processes for this specific technology.

This streamlined access is a key milestone in a national strategic initiative to accelerate the availability of peripheral IV site monitoring across England. The structured pathway, which anticipates an initial expansion over an 18-month period, aims to move the technology from successful pilot programs to a broader standard of care. This will impact numerous departments, from oncology units delivering high-risk chemotherapy to pediatric wards and busy emergency rooms.

With monitors, sensors, and support materials now directly accessible through the NHS Supply Chain, the focus shifts from procurement to implementation. ivWatch has committed to working with clinicians to support education and evidence generation, ensuring that the adoption of its technology translates directly into the improved patient outcomes and system-wide cost savings that its champions have already demonstrated.